Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00052585 · ClinicalTrials.gov registry record · Phase 2
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00052585: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00052585 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00052585, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of combining gefitinib with fluorouracil, leucovorin, and irinotecan in treating patients who have advanced or recurrent colorectal cancer. Biological therapies such as gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining gefitinib with fluorouracil, leucovorin, and irinotecan may kill more tumor cells
Interventions
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG irinotecan hydrochloride
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2002-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00052585
The ClinicalTrials.gov registry entry for NCT00052585 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which fluorouracil is the first listed.
NCT00052585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00052585 about?
NCT00052585 is a clinical study titled "Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer". Phase II trial to study the effectiveness of combining gefitinib with fluorouracil, leucovorin, and irinotecan in treating patients who have advanced or recurrent colorectal cancer. Biological therapies such as gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor ...
What is the current status of trial NCT00052585?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2002-10.
What interventions are being tested in trial NCT00052585?
The interventions under investigation include: fluorouracil (DRUG), leucovorin calcium (DRUG), irinotecan hydrochloride (DRUG), gefitinib (DRUG).
Who is sponsoring clinical trial NCT00052585?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.